Mawer Investment Management Ltd. Has $101.62 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

Key Points

• Mawer Investment Management Ltd. reduced its stake in Becton, Dickinson and Company by 5.0%, selling 23,438 shares and owning approximately 443,627 shares worth $101.6 million as of the last reporting period.
• Becton, Dickinson reported a quarterly EPS of $3.35, exceeding expectations, but revenue of $5.27 billion fell short of estimates by $0.08 billion.
• The company announced a quarterly dividend of $1.04 per share, translating to an annual yield of 2.27%, with a payout ratio of 79.39%.

Mawer Investment Management Ltd. lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 5.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 443,627 shares of the medical instruments supplier's stock after selling 23,438 shares during the period. Mawer Investment Management Ltd. owned 0.15% of Becton, Dickinson and Company worth $101,617,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. lifted its stake in Becton, Dickinson and Company by 36.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock worth $2,751,187,000 after acquiring an additional 3,219,317 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in Becton, Dickinson and Company by 10.8% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock worth $1,567,654,000 after buying an additional 667,957 shares during the last quarter. Geode Capital Management LLC grew its stake in Becton, Dickinson and Company by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier's stock worth $1,437,161,000 after buying an additional 66,024 shares during the last quarter. Invesco Ltd. lifted its position in Becton, Dickinson and Company by 6.7% during the 4th quarter. Invesco Ltd. now owns 4,265,638 shares of the medical instruments supplier's stock worth $967,745,000 after acquiring an additional 267,436 shares during the period. Finally, Kovitz Investment Group Partners LLC lifted its holdings in shares of Becton, Dickinson and Company by 392.4% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 3,416,665 shares of the medical instruments supplier's stock valued at $775,139,000 after buying an additional 2,722,829 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on BDX shares. Piper Sandler downgraded Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and dropped their price target for the stock from $260.00 to $185.00 in a research report on Friday, May 2nd. Wall Street Zen downgraded Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Raymond James Financial downgraded Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Friday, May 2nd. Citigroup downgraded Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and lowered their price target for the company from $217.00 to $185.00 in a research report on Thursday, May 22nd. Finally, Morgan Stanley lowered their price target on Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating for the company in a research report on Tuesday, May 6th. Eight research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Becton, Dickinson and Company has an average rating of "Hold" and an average price target of $219.22.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares of the company's stock, valued at $881,077.23. The trade was a 19.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP David Shan sold 1,166 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the sale, the executive vice president directly owned 4,575 shares in the company, valued at $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX traded down $2.55 during mid-day trading on Friday, hitting $175.70. The company had a trading volume of 3,420,637 shares, compared to its average volume of 2,635,724. The firm has a market cap of $50.36 billion, a P/E ratio of 33.52, a PEG ratio of 1.37 and a beta of 0.25. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The business's 50-day simple moving average is $174.83 and its 200-day simple moving average is $201.28.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The company had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same quarter last year, the business posted $3.17 earnings per share. The company's revenue was up 4.5% on a year-over-year basis. As a group, analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company's payout ratio is currently 79.39%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.